FS-207
/ Foresight Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
FS-207: A potential best-in-class WRN helicase inhibitor for treating MSI-H cancers
(AACR 2026)
- "Our findings position FS-207 as a promising, potentially best-in-class WRN helicase inhibitor for the treatment of MSI-H cancers, owing to its superior efficacy, durability, and selectivity. FS-207 is poised to enter clinical trials in 2026."
MSI-H • Microsatellite Instability • Oncology • MSI • WRN
1 to 1
Of
1
Go to page
1